Our work at AstraZeneca is among the most exciting I’ve experienced in my 20+ years spent in research. We have a rich and growing pipeline of new molecular entities and marketed therapies that have the potential to address unmet needs, including in hard-to-treat diseases. Every day, we are pushing the boundaries of science and challenging the status quo to deliver practice-changing medicines. As AstraZeneca and Alexion Chief Medical Officer, I am responsible for ensuring that patients, physicians and regulatory agencies are provided with information on the safe and appropriate use of our medicines. I lead patient safety and quality assurance activities for our entire portfolio – from investigational new drugs to established products. Additionally, as Oncology Chief Development Officer, I lead AstraZeneca’s late-stage Oncology portfolio of innovative medicines and immunotherapies through global clinical development and regulatory submissions. In this role, I oversee a team of clinical development and operations colleagues around the world, who are currently responsible for a broad portfolio of potential medicines, and more than 160 studies spanning multiple Oncology indications. Before joining AstraZeneca, I held a variety of clinical development leadership roles at Pfizer and at Novartis Pharmaceuticals. Over the last several years, I have lectured extensively on topics including immunotherapy clinical trials, breast cancer and clinical development of PI3K inhibitors. I have published on a wide range of cancer topics, authoring 50 peer-reviewed papers and more than 100 conference abstracts. I have also generated several patents for cancer treatment combinations and regimens. A medical oncologist by training, I earned my medical degree from Marche Polytechnic University and received Medical Oncology training at the Royal Marsden Hospital, Kaplan Comprehensive Cancer Center and the European Institute of Oncology.